Skip to main content

Journal Club

Tumor/Skull Base

The somatic genomic landscape of glioblastoma.

Cell | 2013

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/j.cell.2013.09.034

PMID

24120142

PICO

Population

Patients with glioblastoma (GBM)

Intervention

Comprehensive genomic characterization

Comparator

No direct comparator; descriptive analysis

Outcomes

Identification of somatic alterations, molecular subtypes, and correlations with clinical features

Design

Type

Observational cohort study

Randomized

No

Multicenter

Yes

Blinded

Not applicable: genomic analysis

Follow-up

Not specified for all patients; survival data analyzed

Primary endpoint

Description of somatic genomic alterations in GBM

Secondary endpoints

  • Correlation of molecular subtypes with survival
  • Identification of novel mutated genes
  • Analysis of pathway alterations

Practice impact

What this means

This TCGA study characterizes genomic alterations in over 500 GBM tumors, defining molecular subtypes (proneural, mesenchymal, classical) and identifying frequent mutations in TERT promoter and EGFR. It links the G-CIMP phenotype to better survival in the proneural subtype. While not directly therapeutic, it establishes a genomic framework for future targeted trials and prognostic stratification in neuro-oncology.

Bottom line

This study provides a foundational genomic map of GBM, identifying key alterations and subtypes that inform molecular classification and potential therapeutic targets.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

  • Large-scale genomic data supports molecular subtyping in clinical trials
  • Identifies EGFR and TERT as high-frequency targets
  • Correlates G-CIMP with improved survival, guiding prognostic stratification

What would change my mind

  • Prospective validation of subtype-specific treatment responses
  • Integration of genomic data with standardized clinical outcomes in diverse cohorts
  • Demonstration of therapeutic impact targeting identified alterations

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low for descriptive genomic analysis; potential selection bias from TCGA cohort

Confounding

Clinical and treatment heterogeneity not fully controlled

Missing data

Not explicitly addressed; likely minimal for genomic data

Multiplicity

High due to multiple genomic comparisons; no correction reported

Notes

  • Large sample size enhances detection power
  • Standardized TCGA protocols reduce technical variability

Stats check

NNT

N/A

Effect sizes

  • TERT promoter mutations in 83% of GBMs
  • EGFR alterations in 57% of classical subtype

Absolute effects

  • Median survival 12.6 months for mesenchymal subtype
  • G-CIMP phenotype associated with 150-week median survival

Concerns

  • No adjustment for multiple testing in genomic discoveries
  • Survival analyses may be underpowered for subgroup comparisons

External validity

Who it applies to

Adult patients with histologically confirmed GBM

Who it does not

Pediatric GBM, low-grade gliomas, non-TCGA cohort patients

Generalizability notes

  • Findings representative of TCGA cohort; may not reflect all clinical populations
  • Genomic alterations may vary by institution and treatment history

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 462 Introduction

quote

We describe the landscape of somatic genomic alterations based on multidimensional and comprehensive characterization of more than 500 glioblastoma tumors (GBMs).

claim_id

stats_check.effect_sizes

locator

p. 465 Results

quote

TERT promoter mutations are present in 83% of GBMs.

claim_id

practice_impact.bottom_line

locator

p. 476 Discussion

quote

These data will facilitate the discovery of therapeutic and diagnostic target candidates, the validation of research and clinical observations.

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years